Latest Conference Articles

Axi-cel (axicabtagene ciloleucel; Yescarta) maintained a complete remission rate of 40% with a median follow-up of 15.4 months for patients with refractory, aggressive non-Hodgkin lymphoma.

The CAR T-cell therapy tisagenlecleucel (Kymriah) achieved an overall response rate of 53.1% in adult patients with relapsed/refractory diffuse large B-cell lymphoma.

Treatment with the BCMA-directed CAR T-cell therapy bb2121 induced complete remissions for 56% of patients with relapsed/refractory multiple myeloma.

The phase III ECHELON-1 study in Hodgkin lymphoma compared the use of A+AVD with standard chemotherapy of doxorubicin, bleomycin, vinblastine, and dacarbazine.

Treatment using BLU-285 (Avapritinib) induced clinically significant activity in patients with an advanced or aggressive form of systemic mastocytosis, according to data from an ongoing phase I trial.

The combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) elicited a complete response (CR) or CR with incomplete hematologic recovery rate of 47% for patients with relapsed/refractory chronic lymphocytic leukemia.

The anti-CCR4 monoclonal antibody mogamulizumab reduced the risk of progression or death by 47% compared with vorinostat (Zolinza) in previously treated patients with cutaneous T-cell lymphoma.

Kerry Rogers, MD, Assistant Professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of early intervention with ibrutinib (Imbruvica) in patients with asymptomatic, high-risk chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.

Matthew S. Davids, MD, Associate Director, Dana-Farber Cancer Institute Center for Chronic Lymphocytic Leukemia, discusses a study that explored optimizing checkpoint blockade as a treatment for relapsed hematologic malignancies after allogenic hematopoietic cell transplantation.

The investigational BTK inhibitor zanubrutinib (BGB-3111) demonstrated promising clinical activity in patients with non-Hodgkin lymphoma.

Lenalidomide (Revlimid) plus rituximab (Rituxan) is a feasible combination that is also safe and active, as initial and maintenance therapy for patients with mantle cell lymphoma.

Treatment using oral rivaroxaban (Xarelto) reduced venous thromboembolism (VTE) recurrence among patients with cancer, according to results from the select-d trial.

Monotherapy with an antibody drug conjugate targeting the transmembrane protein LIV-1 had encouraging antitumor activity in a phase 1 study of patients with heavily pretreated TNBC.

Enzalutamide (Xtandi) added to exemestane improved progression-free survival in patients with hormone receptor-positive advanced breast cancer and no prior endocrine therapy who were positive for a gene signature-based biomarker indicating androgen receptor-signaling.

Trastuzumab deruxtecan (ds-8201a), a HER2-targeting antibody-drug conjugate, demonstrated significant clinical activity in heavily pretreated patients with HER2-expressing metastatic breast cancers.

Detection of positive circulating tumor cells in the blood 5 years after a breast cancer diagnosis was associated with an increased risk for late recurrence in women with HR–positive, HER2-negative breast cancer

Treatment with the combination of pembrolizumab (Keytruda) and eribulin (Halaven) demonstrated a 26.4% objective response rate for patients with metastatic triple-negative breast cancer.

Harold Burstein, MD, PhD, medical oncologist, Dana-Farber Cancer Institute discusses some key findings from the follow-up data from the SOFT trial.

Losing even some extra weight significantly reduces the risk of breast cancer for postmenopausal women, expert says.

Neoadjuvant treatment with abemaciclib (Verzenio) plus anastrozole induced complete cell cycle arrest as measured by Ki67 for 67.8% of patients with HR-positive/HER2-negative early-stage breast cancer.

Older women with HR–positive breast cancer treated with a CDK4/6 inhibitor may derive a progression-free survival benefit similar to that seen in their younger counterparts

The PARP inhibitor talazoparib reduced the risk of disease progression or death by 46% versus chemotherapy in patients with BRCA-positive advanced breast cancer.

Dawn Hershman, MD, MS, professor of Medicine and Epidemiology, Columbia University Medical Center, discusses the use of acupuncture to treat joint pain caused by aromatase inhibitors in patients with breast cancer.

Substituting nab-paclitaxel (Abraxane) for solvent-based paclitaxel as neoadjuvant chemotherapy improved disease-free survival in patients with high-risk early breast cancer.

Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses some questions that remain after the recent phase II MEDIOLA trial.

Halle Moore, MD, medical oncologist, the Cleveland Clinic, discusses the use of GnRH agonists to preserve ovarian function and fertility in women with breast cancer.

Treatment with nab-paclitaxel showed promising improvements in overall survival and progression-free survival compared with standard paclitaxel for patients with metastatic triple-negative breast cancer.

Key opinion leaders share their insight on the pivotal and highly anticipated abstracts across hematologic malignancies, including lymphoma, leukemia, and multiple myeloma, ahead of 2017 ASH Annual Meeting and exactly how these findings could be implemented in and affect clinical practice.

Investigators with the Austria Breast and Colorectal Cancer Study Group announced today that years can safely be shaved off anastrozole (Arimidex) treatment without affecting disease-free survival postmenopausal HR-positive breast cancer.

A mix of traditional and customized acupuncture techniques proved effective in reducing pain and stiffness associated with aromatase inhibitor (AI) therapy in women with early-stage breast cancer.